{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T02:51:52Z","timestamp":1767927112808,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1007\/s12325-013-0030-7","type":"journal-article","created":{"date-parts":[[2013,6,7]],"date-time":"2013-06-07T02:43:51Z","timestamp":1370573031000},"page":"528-540","source":"Crossref","is-referenced-by-count":5,"title":["Long-Term Effects of Beraprost Sodium on Arteriosclerosis Obliterans: a Single-Center Retrospective Study of Japanese Patients"],"prefix":"10.1007","volume":"30","author":[{"given":"Tadashi","family":"Arai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,6,8]]},"reference":[{"key":"30_CR1","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jvs.2006.12.037","volume":"45","author":"L Norgren","year":"2007","unstructured":"Norgren L, Hiatt WR, Dormandy JA, et al. TASC II Working Group. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45:S5\u201367.","journal-title":"J Vasc Surg"},{"key":"30_CR2","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1253\/circj.71.995","volume":"71","author":"T Yamazaki","year":"2007","unstructured":"Yamazaki T, Goto S, Shigematsu H, et al. Prevalence, awareness and treatment of cardiovascular risk factors in patients at high risk of atherothrombosis in Japan. Circ J. 2007;71:995\u20131003.","journal-title":"Circ J"},{"key":"30_CR3","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.2337\/diabetes.45.1.101","volume":"45","author":"N Tsushima","year":"1996","unstructured":"Tsushima N, Matsuo H, Hayashi T, Homma S. The clinical features and treatment of arteriosclerosis obliterans with diabetes. Diabetes. 1996;45:S101\u20134.","journal-title":"Diabetes"},{"key":"30_CR4","first-page":"2","volume":"29","author":"H Shigematsu","year":"2010","unstructured":"Shigematsu H, Nishibe T, Obitsu Y, et al. Three-year cardiovascular events and disease progress in patients with peripheral arterial disease: results from the Japan Medication Therapy for Peripheral Arterial Disease (J-METHOD). Int Angiol. 2010;29:2\u201313.","journal-title":"Int Angiol"},{"key":"30_CR5","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/jcp.21214","volume":"214","author":"H Lin","year":"2008","unstructured":"Lin H, Lee JL, Hou HH, Chung CP, Hsu SP, Juan SH. Molecular mechanisms of the antiproliferative effect of beraprost, a prostacyclin agonist, in murine vascular smooth muscle cells. J Cell Physiol. 2008;214:434\u201341.","journal-title":"J Cell Physiol"},{"key":"30_CR6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ijcard.2007.12.119","volume":"132","author":"H Atsuta","year":"2009","unstructured":"Atsuta H, Uchiyama T, Kanai H, et al. Effects of a stable prostacyclin analogue beraprost sodium on VEGF and PAI-1 gene expression in vascular smooth muscle cells. Int J Cardiol. 2009;132:411\u20138.","journal-title":"Int J Cardiol"},{"key":"30_CR7","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1476-5381.1986.tb11174.x","volume":"89","author":"T Akiba","year":"1986","unstructured":"Akiba T, Miyazaki M, Toda N. Vasodilator actions of TRK-100, a new prostaglandin I2 analogue. Br J Pharmacol. 1986;89:703\u201311.","journal-title":"Br J Pharmacol"},{"key":"30_CR8","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1161\/01.CIR.102.4.426","volume":"102","author":"M Li\u00e8vre","year":"2000","unstructured":"Li\u00e8vre M, Morand S, Besse B, Fiessinger JN, Boissel JP. Oral beraprost sodium, a prostaglandin I2 analogue for intermittent claudication a double-blind randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group. Circulation. 2000;102:426\u201331.","journal-title":"Circulation"},{"key":"30_CR9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3820\/jjpe1996.9.45","volume":"9","author":"H Origasa","year":"2004","unstructured":"Origasa H, Ikeda Y, Shimada K, Shigematsu H. Oral beraprost sodium as a prostaglandin I2 analogue for vascular events in patients with peripheral arterial disease: meta-analysis of two placebo-controlled randomized trials. Jpn J Pharmacoepidemiol. 2004;9:45\u201351.","journal-title":"Jpn J Pharmacoepidemiol"},{"key":"30_CR10","first-page":"499","volume":"21","author":"R Fontaine","year":"1954","unstructured":"Fontaine R, Kim M, Kieny R. Surgical treatment of peripheral circulation disorders. Helv Chir Acta. 1954;21:499\u2013533.","journal-title":"Helv Chir Acta"},{"key":"30_CR11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1161\/CIRCULATIONAHA.107.721878","volume":"118","author":"RL Pande","year":"2008","unstructured":"Pande RL, Perlstein TS, Beckman JA, Creager MA. Association of insulin resistance and inflammation with peripheral arterial disease: the National Health and Nutrition Examination Survey, 1999\u20132004. Circulation. 2008;118:33\u201341.","journal-title":"Circulation"},{"key":"30_CR12","first-page":"889","volume":"42","author":"H Kumakura","year":"2002","unstructured":"Kumakura H, Ogino T, Sugito Y, et al. Survival of patients with arteriosclerosis obliterans with special reference to risk factors, complications and methods of treatment. J Jpn Coll Angiol. 2002;42:889\u201395.","journal-title":"J Jpn Coll Angiol"},{"key":"30_CR13","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1161\/CIRCULATIONAHA.109.865600","volume":"120","author":"C Diehm","year":"2009","unstructured":"Diehm C, Allenberg JR, Pittrow D, et al. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation. 2009;120:2053\u201361.","journal-title":"Circulation"},{"key":"30_CR14","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1161\/CIR.0b013e31822e80c3","volume":"124","author":"TW Rooke","year":"2011","unstructured":"Rooke TW, Hirsch AT, Misra S, et al. 2011 ACCF\/AHA focused update of the Guideline for the management of patients with peripheral artery disease (Updating the 2005 Guideline): a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines. Circulation. 2011;124:2020\u201345.","journal-title":"Circulation"},{"key":"30_CR15","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1097\/00005344-199606000-00004","volume":"27","author":"M Lievre","year":"1996","unstructured":"Lievre M, Azoulay S, Lion L, Morand S, Girre JP, Boissel JP. A dose-effect study of beraprost sodium in intermittent claudication. J Cardiovasc Pharm. 1996;27:788\u201393.","journal-title":"J Cardiovasc Pharm"},{"key":"30_CR16","first-page":"1401","volume":"38","author":"T Katsumura","year":"1989","unstructured":"Katsumura T, Masaki H. Antiaggregation effect of TRK-100 (prostaglandin I2 analogue) in chronic arterial occlusive disease. J N Rem Clin. 1989;38:1401\u20136.","journal-title":"J N Rem Clin."},{"key":"30_CR17","doi-asserted-by":"crossref","unstructured":"Dorner\u00ae [product information]. Tokyo, Japan: Toray Industries Inc.; 2011.","DOI":"10.1016\/S1365-6937(11)70021-1"},{"key":"30_CR18","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1001\/jama.2009.623","volume":"301","author":"JS Berger","year":"2009","unstructured":"Berger JS, Krantz MJ, Kittelson JM, et al. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA. 2009;301:1909\u201319.","journal-title":"JAMA"},{"key":"30_CR19","unstructured":"[No authors listed] Cilostazol: new drug. Intermittent claudication: too little efficacy, too many risks. Prescrire Int. 2009;18:56\u20139."},{"key":"30_CR20","first-page":"140","volume":"29","author":"F Gamssari","year":"2002","unstructured":"Gamssari F, Mahmood H, Ho JS, et al. Rapid ventricular tachycardias associated with cilostazol use. Tex Heart Inst J. 2002;29:140\u20132.","journal-title":"Tex Heart Inst J"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-013-0030-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-013-0030-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-013-0030-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,14]],"date-time":"2019-07-14T18:07:49Z","timestamp":1563127669000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-013-0030-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["30"],"URL":"https:\/\/doi.org\/10.1007\/s12325-013-0030-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}